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ABSTRACT
Objectives: We developed a pragmatic modelling approach to estimate the impact of treatment 
as prevention (TasP); outreach testing strategies; and pre-exposure prophylaxis (PrEP) on the 
epidemiology of HIV and its associated pharmaceutical expenses.
Methods: Our model estimates the incremental health (in terms of new HIV diagnoses) and 
budget impact of two prevention scenarios (outreach+TasP and outreach+TasP+PrEP) against 
a ‘no additional prevention’ scenario. Model parameters were estimated from reported 
Belgian epidemiology and literature data. The analysis was performed from a healthcare payer 
perspective with a 15-year-time horizon. It considers subpopulation differences, HIV infections 
diagnosed in Belgium having occurred prior to migration, and the effects of an ageing HIV 
population.
Results: Without additional prevention measures, the annual number of new HIV diagnoses rises 
to over 1350 new diagnoses in 2030 as compared to baseline, resulting in a budget expenditure 
of €260.5 million. Implementation of outreach+TasP and outreach+TasP+PrEP results in a 
decrease in the number of new HIV diagnoses to 865 and 663 per year, respectively. Respective 
budget impacts decrease by €20.6 million and €33.7 million.
Conclusion: Foregoing additional investments in prevention is not an option. An approach 
combining TasP, outreach and PrEP is most effective in reducing the number of new HIV 
diagnoses and the HIV treatment budget. Our model is the first pragmatic HIV model in Belgium 
estimating the consequences of a combined preventive approach on the HIV epidemiology and 
its economic burden assuming other prevention efforts such as condom use and harm reduction 
strategies remain the same.
Introduction
The prevalence of HIV in the Western world is still 
rising [1]. Improved efficacy of treatment with antiret-
roviral therapy (ART) and improved follow-up have 
turned HIV into a condition that can be successfully 
managed on a long-term basis [2]. HIV incidence has 
however been difficult to control, and despite the still 
higher than average use of preventive measures such as 
condom use [3], high-risk behaviour among people at 
risk for HIV is still a concern [4–6]. New HIV diagnosis 
rates in Belgium remain high with respect to the West 
European WHO region [7]. The lack of control of the 
epidemic leads to an increasing economic burden related 
to the management of a continuously increasing num-
ber of HIV patients. A significant part of this economic 
burden is associated with the long-term pharmaceutical 
management of these patients [8,9].
Several large trials have shown the effect of ART use 
to reduce HIV transmission and acquisition [10–13]. In 
this context, the panel of available preventive strategies, 
including treatment as prevention, has enlarged. In order 
to counter the increasing epidemiologic and economic 
impact, a stronger focus on the use of these preventive 
measures is required. Different preventive strategies are 
possible and might be combined:
•  overall population-based primary prevention strat-
egies such as condom and lubricant distribution 
and awareness raising campaigns;
•  reducing the number of patients unaware of their 
infection by identifying previously undiagnosed 
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HIV patients (for instance, outreach programmes 
designed to access people at high risk of acquiring 
HIV, including testing of people unaware of their 
HIV status);
•  reducing the number of diagnosed patients not on 
ART through prompt initiation of treatment in all 
patients diagnosed with HIV, including those with 
high CD4 levels (immediate ART/treatment as pre-
vention – TasP);
•  ensure an optimal retention in care and adherence 
of the HIV patients receiving ART;
•  preventing HIV infection through prophylactic 
treatment after a possible recent exposure (post- 
exposure prophylaxis – PEP);
•  preventing HIV infection through prophylactic 
treatment in uninfected individuals at high risk of 
infection (pre-exposure prophylaxis – PrEP).
The projected impact of these measures on the epi-
demiology and economic burden of HIV has not been 
adequately studied in a Belgian context. Health policy 
makers have limited resources and seek evidence to 
better allocate these resources into those strategies and 
measures that increase health and are cost-effective. 
Modelling techniques are required to better understand 
the implication of different strategic choices on the epi-
demiology of HIV, patient outcomes, health economic 
benefits and impacts on health care systems.
Aim
The aim of this paper is to present a new pragmatic 
modelling approach, the BELHIVPREV (Belgian HIV 
Prevention) model, to estimate the impact of (1) imme-
diate ART/TasP; (2) reducing the number of patients 
unaware of their infection (outreach); and (3) PrEP; on 
the epidemiology of HIV and the associated pharmaceu-
tical expenses. In a secondary analysis, the added value 
of increased investments in other primary prevention 
interventions will also be assessed. This secondary anal-
ysis is not part of the current paper.
Methods
Modelling approach
We developed a predictive model estimating the annual 
number of new HIV diagnoses and the total number of 
HIV patients in medical follow-up.
The model outcomes included the annual estimated 
number of new HIV diagnoses, the annual estimated 
number of patients in medical follow-up, and the esti-
mated total treatment cost for routine HIV and pre-
ventive treatment for various preventive scenarios. In 
addition, the annual and total cost of treating newly 
and previously infected HIV patients is included in the 
analyses to gain an understanding of the potential eco-
nomic benefits of preventive treatment strategies. Model 
parameters were estimated based on reported Belgian 
HIV epidemiology figures from 2007 to 2015 supple-
mented by data extracted from literature.
The model estimated the incremental budget and 
health (in terms of total number of patients on HIV 
treatment and the annual number of new HIV infec-
tions) impact of different scenarios in which the imple-
mentation of one or more types of prevention strategies 
were assumed against a base case scenario in which no 
additional effort on prevention was assumed to occur. 
Thereby, the (pharmaceutical) costs and (epidemiolog-
ical) effects of preventive measures such as outreach 
testing, immediate ART/TasP and PrEP as well as the 
(pharmaceutical) cost for the routine treatment of HIV-
positive patients were taken into account.
Analysis perspective
The budget analysis was performed from the perspec-
tive of the pharmaceutical healthcare payer budget. 
Consequently, it did not consider non-pharmaceutical 
costs, such as cost of outreach testing activities, diagnosis 
and HIV patient follow-up.
Time horizon
The model results included the health and budget impact 
of the preventive strategies for a 15-year-time horizon, 
up to 2030. This time horizon was selected to investi-
gate mid- to long-term effects while minimizing poten-
tial distortion of outcomes associated with long-term 
extrapolations.
Model framework
The model consisted of three core components:
(1)  An estimation of the annual number of new 
HIV diagnoses, based on the estimate of the 
total number of ‘infectious’ patients and the 
degree of their infectiousness.
(2)  Estimation of the annual number of patients 
in medical follow-up, based on the calculated 
estimate of new HIV diagnoses entering fol-
low-up, minus death and dropout added to 
those already in follow-up from previous 
years.
(3)  Integration of the effect of increasing the num-
ber of diagnosed patients on ART (immediate 
ART/TasP), decreasing the number of undiag-
nosed patients (outreach testing) and reducing 
the number of new HIV infections through 
prophylactic treatment (PrEP).
In the following paragraphs, we outline the dynamics 
and data inputs associated with these three components. 
More details on the model’s mechanics and calculations 
can be found in Appendix 1.
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(1)  Estimating the annual number of new HIV 
diagnoses
To estimate the annual number of new HIV diagno-
ses, first an estimate of the total ‘infectious’ population 
was calculated. For the purposes of our model, an HIV 
patient was deemed to be ‘infectious’ if:
(a)  the patient was undiagnosed;
(b)  the patient was diagnosed but had not initiated 
treatment;
(c)  the patient was being treated but had not achieved 
a controlled (undetectable; <200 copies/ml) viral 
load.
The number of undiagnosed HIV patients has not 
clearly been established. Based on available research and 
modelling data, it is assumed that between 10% and 20% 
of the current HIV population is undiagnosed [14]. For 
our model, we used an estimate of 12% undiagnosed 
HIV patients at the end of 2014. To simulate the effect 
of currently ongoing efforts in identifying undiagnosed 
patients, we furthermore assumed this percentage to 
gradually decrease to 10% in 2020, even in the absence 
of additional investments in prevention, after which it 
was assumed to remain constant.
The number of diagnosed patients not having ini-
tiated treatment was determined from reported per-
centages of patients on ART. At the end of 2013, 89% 
of patients followed up in an AIDS Reference Centre 
were on ART treatment [15]. In the absence of addi-
tional efforts, we assumed this percentage to gradually 
increase up to 92% in 2020, after which it was assumed 
to remain constant.
Finally, the model assumed that a proportion of 
patients on ART treatment remain infectious. This pro-
portion was approximated based on reported numbers 
of patients not achieving a viral load (VL) of <200 cop-
ies/ml after receiving at least 6 months of antiretroviral 
therapy. According to Sasse et al., 96% of patients treated 
in an AIDS reference centre at the end of 2015 achieved a 
VL < 200 [14], meaning that 4% of treated patients were 
still infectious. This percentage was assumed to remain 
constant over time.
Using this approach, the total number of ‘infectious 
patients’ was calculated and compared to the reported 
number of newly diagnosed HIV infections [14] for 
each year between 2007 and 2015. The average result of 
this ratio was 23.7%. We labelled this ratio as a propa-
gation factor: for each 1000 infectious patients, there 
are 237 new diagnoses. This propagation factor was 
then assumed to remain constant in the base case for 
future extrapolation. Based on reported figures for the 
Belgian continuum of care [16], we assumed around 
90% of these newly diagnosed patients entered HIV 
care.
(2)  Estimating the annual number of patients in 
medical follow-up
The estimated annual number of patients in medical 
follow-up was calculated year-to-year based on:
•  the number of patients in medical follow-up at the 
end of the previous year;
•  the number of newly diagnosed patients expected 
to enter follow-up, calculated as detailed above;
•  the expected mortality rate;
•  a ‘net loss’ factor, reflecting the net difference in 
patients lost to follow-up during that year and 
patients re-entering follow-up in the same year 
having been lost to follow-up in previous years 
[16].
The estimated mortality rate was calculated from 
the annual reported mortality and the annual number 
of newly diagnosed patients or patients in medical fol-
low-up between 2007 and 2015 (0.3%) [14]. The estimate 
of the annual number of patients in medical follow-up 
was obtained by adding new diagnoses to, and subtract-
ing estimated mortality from the previous estimate of the 
yearly number of patients in medical follow-up. This was 
compared to reported numbers from 2007 and 2015 [14] 
to calculate the ‘net loss’ factor (2.1%), which was then 
assumed to remain constant for future extrapolation. 
This net loss is the result of patients lost to follow up and 
other patients having been lost to follow up for a while 
but entering again into the system.
(3)  Integrating the effects of outreach, immediate 
ART/TasP and PrEP
The effects of outreach and immediate ART/TasP 
were calculated in the model as a result of a decrease in 
the number of undiagnosed and untreated HIV patients, 
respectively.
To integrate the effect of PrEP, a stepwise approach 
was implemented: first, a theoretical annual ‘population 
at risk’ was defined from the calculated annual new HIV 
diagnoses and published HIV acquisition rates [17–19] 
(how many times the virus is likely to be acquired per 
100 persons per year). Based on the ratio between both 
parameters, the size of the ‘pool’ of the population at 
risk can be derived. The impact of PrEP was modelled 
through a calculated decrease in the size of the annual 
‘population at risk’, taking into account published PrEP 
effectiveness rates [17–19]. Finally, the estimated num-
ber of infections avoided was calculated by recalculat-
ing the annual number of new HIV diagnoses from the 
reduced ‘population at risk’, using the aforementioned 
HIV infection rates.
Taking into account (sub)population differences
The HIV epidemic in Belgium is mainly concentrated 
in two subpopulations: men who have sex with men 
and sub-Saharan African migrants having acquired the 
disease through heterosexual contact [14]. Given the 
concentrated epidemic in Belgium, prevention is also 
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account an expected 60% price decrease to €216.34 
during 2017 due to the introduction of generics in 
July and cluster opening in October.
As stated previously, the perspective of the study 
was from the pharmaceutical budget holder and costs 
of outreach, testing, diagnosis and follow up costs were 
not included.
Analysis scenarios
The budget and health impact of combined prevention 
was assessed by two prevention scenarios compared to 
the same base case analysis.
The base-case analysis assumed:
•  No additional preventive effort beyond the lim-
ited reduction of the percentage of undiagnosed 
patients (down from 12% in 2014 to 10% in 2020) 
and an increase in patients on ART (up to 92% in 
2020 from 89% in 2013);
Hence, the base case represents a realistic scenario 
consisting of a spontaneous small improvement in the 
number of diagnosed and treated patients.
The first prevention (Outreach+TasP) scenario 
assumed:
•  Additional efforts in reducing the percentage of 
undiagnosed patients through outreach testing 
programs leading to an additional 5% reduction 
over 5 years, reducing the absolute percentage of 
undiagnosed patients to 5%;
•  Additional efforts in increasing the percentage of 
diagnosed patients on ART through immediate 
ART/TasP (additional 4% increase in ART treat-
ment over 5  years, increasing the percentage of 
diagnosed patients on ART to 96%);
The second prevention scenario (Outreach+TasP+ 
PrEP) assumed in addition to the preventive efforts out-
line in the first prevention scenario, a treatment of up to 
2633 people with PrEP, of which 90% MSM.
Model validation and sensitivity analyses
We validated the model with historically available data, 
starting from 2007 data and extrapolating up until 2015 
and comparing the model’s predictions to the published 
data for that period.
Additionally, we tested the sensitivity of the model 
through a one-way sensitivity analysis (OWSA) on the 
expected budget impact and estimated number of new 
HIV diagnoses in 2030. The one-way sensitivity analysis 
included the following parameters: additional effort in 
reducing the number of undiagnosed patients (outreach 
testing); additional effort in increasing the percentage of 
patients on ART (immediate ART/TasP); the number 
of patients treated with PrEP; the annual cost of HIV 
tailored to these two priority groups. As a result, the 
model inputs needed for the above-described dynamics 
were different between different HIV subpopulations:
•  men who have sex with men (MSM);
•  heterosexuals;
•  people who inject drugs (PWID).
The model allowed us to specify subpopulation-spe-
cific values for the following two parameters: the per-
centage of undiagnosed patients, with lower percentages 
for MSM (Odds Ratio of 0.39 for MSM [20]); and the 
HIV acquisition and transmission rates used to calcu-
late the size of the ‘population at risk’ for estimation of 
the impact of PrEP: 6.6 per 100 person years for MSM; 
3.1 per 100 person years for heterosexuals and 0.68 for 
PWID [17–19].
Moreover, the model accounted for the difference in 
HIV infectiousness depending on the stage of the HIV 
care continuum in which an infectious patient can be 
(undiagnosed, diagnosed but untreated, treated and VL 
≥ 200 copies/ml) [21]. To achieve this, the ‘propagation 
factor’ used to calculate the estimated number of annual 
new HIV diagnoses was scaled to take into account the 
proportion of patients in each stage of the care contin-
uum for each year in the model.
Finally, the model took into account that a number of 
newly diagnosed HIV patients were migrants who had 
acquired HIV in their home country prior to their arrival 
in Belgium. These patients were not expected to be influ-
enced by Belgian efforts in HIV prevention. Our model 
assumed that 71% of HIV infections newly diagnosed 
in migrants were acquired outside of Belgium [22]. The 
resulting estimated number of new HIV diagnoses was 
assumed not to change regardless of the additional pre-
vention effort simulated.
Including the effects of an aging HIV Population
The population living with HIV is on average getting 
older and the average age of people living with HIV is 
expected to continue to increase [23]. The model applied 
an expected gradual age increase from 41.6 years in 2010 
to 54.3 years in 2030, based on the results of an extrapo-
lation model applied to the Belgian HIV population. This 
age increase resulted in a higher background mortality 
over time. Background mortality rates were extracted 
from 2015 Belgian mortality tables [24].
Cost data
The model included the following costs:
•  The pharmaceutical cost for ART treatment esti-
mated at €1,027.5 per month [25]
•  The cost-for PrEP-treatment estimated at €527.36 
per month (based on 2017 RIZIV/INAMI prices). 
For the cost of PrEP treatment, the model took into 
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Scenario 2 vs. baseline
In comparison to the baseline scenario, implementation 
of Outreach+TasP+PrEP resulted in a pronounced ini-
tial decline in new diagnoses with followed by a grad-
ual increase from 2021 on. In comparison to Scenario 
1, the initial decrease is slightly more pronounced and 
the gradual uptake less after the initial decrease is less 
important. This resulted in an expected reduction to 663 
annual new HIV diagnoses in 2030. From a budgetary 
perspective, the outreach+TasP scenario is expected to 
be cost-saving from 2024 onwards (€1.9 million to €33.7 
million annual savings from 2024 to 2030 – Figure 3).
Total budget – scenario 1 and 2 vs. baseline
In the absence of additional prevention and when main-
taining current prevention efforts, the total (pharmaceu-
tical) budget for HIV treatment is expected to increase 
to over €260 million in 2030. Even taking into account 
the additional treatment cost for immediate ART/TasP 
and PrEP, this total budget expenditure is expected to be 
significantly reduced, with expected total expenditures 
in 2030 of €239 million and €227 million for scenario 1 
and scenario 2, respectively (Figure 4).
One-way sensitivity analyses
The results of the one-way sensitivity analysis are illus-
trated in the tornado diagram in (Figure 5). The tornado 
treatment; and the monthly cost of PrEP. Parameters 
were varied between 70% and 130% of their baseline 
values.
Results
Validation with historical data
Figure 1 illustrates the results of the model’s valida-
tion. Estimated values for number of patients in med-
ical follow-ups and newly diagnosed patients entering 
follow-up differed no more than 1.7% and 3.9% from 
actually recorded values, respectively.
Scenario 1 vs. baseline
In the absence of additional prevention and when main-
taining current prevention efforts, the estimated number 
of annual new HIV diagnoses, after an initial period 
of decline, was expected to increase to over 1350 new 
diagnoses per year by 2030.
Implementation of Outreach+TasP resulted in a 
pronounced initial decline in new diagnoses, coupled 
with a gradual increase from 2020 on. This resulted in 
an expected reduction in the annual number of new 
HIV diagnoses from the 1350 projected in the base-
line scenario down to 865 in 2030. From a budgetary 
perspective, the Outreach+TasP scenario is expected to 
be cost-saving from 2025 onwards (€3 million to €20.6 
million annual savings from 2025 to 2030 – Figure 2).
Figure 1. Results of the model validation comparing actual to estimated values for the number of patients in medical follow-up and 
new HIV diagnoses.
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estimated budget impact in 2030; and to the number of 
undiagnosed patients identified and initiated on ART 
(% outreach in the model) with respect to the number 
of new HIV diagnoses expected in 2030.
Discussion
The purpose of this model was to assess the possible 
impact of a series of preventive measures compared to 
a base-case scenario whereby no additional efforts are 
undertaken.
diagrams list, from top to bottom, in decreasing order 
the parameters the model is most sensitive to. Dark bars 
indicate the deviation from the base case result (33.7 
million € for the estimated budget impact and 663 new 
diagnoses for the estimated number of new diagnoses) 
for the increase of the parameter specified to 130% of 
its base case value. Light bars indicate the deviation 
from the base case result for a decrease of the specified 
parameter to 70% of its base case value. The diagrams 
demonstrate that our model is most sensitive to the cost 
of HIV treatment with respect to its estimates for the 
Figure 2. (Top) Yearly estimates for number of new HIV diagnoses for the outreach+TasP (new world) vs. no additional prevention 
(old world) analysis scenario. (Bottom) Yearly estimates of budget impact (outreach+Tasp additional expenditure/savings versus no 
additional prevention).
60   S. VERMEERSCH ET AL.
‘combined prevention’ and the added value in terms of 
health (new HIV diagnoses) and budget impact.
Our analysis indicates that, without explicit new 
efforts, the number of new HIV diagnoses in Belgium 
is expected to increase by 33% in 2030 when compared 
to 2015. With additional efforts in terms of immediate 
ART/TasP, outreach and PrEP, this figure can be reduced 
by 51% (down to 65% of the 2015 number of new diag-
noses). This would lead to an expected budgetary savings 
of €33.7 million in 2030 alone.
It should be noted that our base case, which presumes 
a natural, gradual increase in the number of patients 
diagnosed and treated, does not yet fully include recent 
efforts in promoting immediate ART/TasP. Since end 
2016, RIZIV/INAMI – the Belgian public healthcare 
insurer – is reimbursing ART for all. The immediate 
ART/TasP included in both scenario 1 and scenario 2 
in our analysis thus now represents the Belgian ‘base 
case’ scenario. We have opted not to include this effect 
in our base case scenario to fully capture the effect of 
Figure 3.  (Top) Yearly estimates for number of new HIV diagnoses for the outreach+TasP+PrEP (new world) vs. no additional 
prevention (old world) analysis scenario. (Bottom) Yearly estimates of budget impact (outreach+Tasp+PrEP additional expenditure/
savings versus no additional prevention).
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of €22 million would still be realized with the multifac-
eted approach. In terms of health impact (number of 
new HIV diagnoses), our model is most sensitive to the 
number of undiagnosed patients additionally diagnosed 
and treated (outreach). This highlights the importance 
of improving performance at the start of the treatment 
cascade: the earlier people are made aware of and treated 
for their HIV infection, the better.
Health-economic models for the prevention of HIV 
have previously been proposed. In practice, however, 
these often relate to health-economic or budget impact 
analyses in a single product [26] or investigating a par-
ticular type of preventive approach [27]. In addition, 
models often either focus on budget or health/cost-ef-
fectiveness impact [26,28,29]. Our model offers an inte-
grated view of different types of prevention programs and 
is specifically focused on the Belgian context. As such, it 
offers a comprehensive analysis framework for investi-
gating budget and healthcare impact of prevention.
As with every model applied in predicting health and 
cost outcomes, the BELHIVPREV model has some lim-
itations. First, some of the data available to populate the 
model were based on assumptions, such as the subpopu-
lation-specific parameter estimates and the estimates of 
the number of undiagnosed patients. Second, the model 
shows macro-level results, and it remains difficult what 
the implications in terms of resources and organizational 
changes would be on a micro-level, i.e. the level of daily 
Based on this analysis, it is clear prevention provides 
good health-economic value, reducing the projected 
burden of disease at an overall cost savings. Investing 
in prevention programmes, therefore, appears cost-ef-
fective. A multifaceted approach would require an initial 
investment via additional drug expenditure that would 
be recovered over time leading to a break-even situation 
by the year 2025. The multifaceted approach combining 
immediate ART/TasP, outreach and PrEP appears the 
most cost-effective.
We investigated the sensitivity of our model to its 
most important determinants in terms of its main out-
comes: cost of treatment (PrEP and HIV treatment) 
for budget impact and the number of patients reached 
through the different preventive efforts (outreach, 
immediate ART/TasP, PrEP) for budget impact and 
health impact (new HIV diagnoses). In terms of budget 
impact, the cost of HIV treatment is the parameter our 
model is most sensitive to. This is unsurprising, given 
that two of the three preventive approaches included in 
our model (outreach and immediate ART/TasP) involve 
diagnosing and/or treating previously undiagnosed and/
or untreated patients, increasing the volume of patients 
on ART. Reducing the cost of ART, either through use 
of generics or specific agreements with pharmaceuti-
cal firms would further increase annual cost savings. 
However, even in the unlikely case of a 30% increase 
in HIV treatment cost by 2030, an annual cost saving 
Figure 4. Estimated total (pharmaceutical) budget for the baseline (no additional prevention), outreach+TasP and outreach+Tasp+PrEP 
scenarios.
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epidemic closely and to compare updated figures with 
the predictions of the model. This would allow recali-
bration of the model in accordance with a PDCA (plan-
do-check-act) policy. Finally, the current results do not 
yet include the impact of ‘general’ prevention measures 
such as community actions and preventive campaigns.
Future work with the BELHIVPREV model will 
include the incorporation of this general prevention 
approach, updating the model data set as new data 
comes in, and refining the model assumptions whenever 
practice. Third, the focus on pharmaceutical costs alone 
does not allow consideration of associated costs, e.g. 
identifying undiagnosed patients through outreach or 
other programs, or the cost impact of reduced hospital-
izations or more effective management of comorbidities. 
Fourth, despite the fact that the model was validated 
against historical data, there remains uncertainty on the 
prediction of evolution of the HIV epidemic and budget 
impact. If the preventive multifaceted approach were to 
be formally introduced, it would be advisable to track the 
Figure 5. Tornado diagram illustrating the OWSA on key model parameters with respect to (top panel) the expected budgetary 
savings realized in 2030 (base case = 33.7 million €) and (bottom panel) the expected number of new HIV diagnoses in 2030 (base 
case = 663 new diagnoses). The OWSA was run on the scenario comparing baseline to outreach+TasP+PrEP.
ACTA CLINICA BELGICA: INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY MEDICINE  63
Republic of Congo. He is interested in tuberculosis, import 
pathology, travel medicine and vaccinations, as well as 
general internal medicine clinic and diagnostics. His main 
research topics include epidemiology of tuberculosis and 
HIV in Africa and Belgium.
Stéphane De Wit is Chief of the Department of Infectious 
Diseases at the Saint-Pierre University Hospital in Brussels. 
He is also Professor of Infectious Diseases at the Free 
University of Brussels. As a clinician and clinical researcher, 
Stéphane De Wit has been active in the field of HIV/AIDS 
since 1983. He is author or co-author of more than 200 arti-
cles and more than 360 communications at conferences. He 
is Coordinator of the Brussels Saint Pierre Cohort, Chair of 
the Belgian HIV Research Consortium BREACH, Chair of 
the COHERE Executive Committee, Founding member and 
Vice- chair of the European NEAT-ID Foundation. He is 
also member and secretary of the Governing Board of the 
European AIDS Clinical Society (EACS). He has been Chair 
of the “8ème Conférence Internationale Francophone HIV/
Hépatites” (AFRAVIH) which was held in Brussels in April 
2016 and co chair of the EACS Standard of care meeting held 
in Brussels in November 2016.
JC Goffard is head of the ULB Erasme AIDS reference centre 
and primary immunodeficiency unit. He is teaching inter-
nal medicine and semiology at medical school of ULB. His 
team is participating in many clinical trials, either academic 
or industry driven.
Marie Laga [MD 1982 Louvain University; MPH 1987 at 
LSHTM; PhD 1990 University of Antwerp] is Professor and 
Head of HIV and Sexual Health group at the Institute of 
Tropical Medicine (ITM) in Antwerp Belgium. Marie and 
her team contributed significantly to HIV prevention science 
in the areas of sexual transmission and its co-factors, pre-
vention programs for vulnerable groups such as female sex 
workers, youth and MSM, evaluation of female controlled 
methods and linkages of sexual and reproductive health. 
In recent years, Marie has become a leading expert in HIV 
prevention, advocating for intensifying HIV Prevention 
worldwide.
Dominique Van Beckhoven is a medical epidemiologist. She 
graduated in medicine at the UCL in 1997 and has worked 
in humanitarian missions with Médecins Sans Frontières 
between 1998 and 2004 in several African countries. After 
having studied public health and nutrition at the LSHTM in 
2005, she joined Epicentre as epidemiologist for nutrition 
surveys and outbreak investigations. Since 2007, she works 
at the Scientific Institute of Public Health (WIV-ISP), as 
responsible of the national HIV cohort in the Epidemiology 
of Infectious Diseases unit.
Lieven Annemans is senior full professor Health Economics 
at the Faculty of Medicine of Ghent University. For 8 years, 
he was chairman of the Flemish Health Council. In 2004 
he was elected President of the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR). 
He also served as cabinet member (2000–2003) to Minister 
of Health Frank Vandenbroucke. Lieven Annemans was 
awarded a Francqui Chair in 2013 and 2016. He is the author 
of the books ‘Health economics for non-economists’ (2008) 
and ‘De prijs van uw gezondheid – is onze gezondheidszorg 
in gevaar?’ (2014). He has authored or co-authored over 250 
international peer reviewed publications in the field of health 
economics.
new data permit investigators to challenge the current 
assumptions.
In conclusion, this is the first pragmatic model in the 
field of HIV in Belgium that allows for an estimation of 
the consequences of a combined preventive approach 
on the HIV epidemiology and its economic burden. The 
current predictions suggest that a combined preventive 
approach would lead to a significant decrease in the 
incidence of the disease and important net savings on 
the pharmaceutical budget, even when not yet explic-
itly including additional general primary prevention 
measures.
Disclosure statement
•  Sebastian Vermeersch: hict has received consultancy 
fees from Gilead Sciences Belgium.
•  Steven Callens: has received grant support from 
ViiV & Gilead and has received honoraria for 
speaking engagements and/or consultancy meet-
ings from the following: Gilead, ViiV, Janssens, 
Merck, Pfizer, MSD & GSK. He has also received 
limited unrestricted funding, paid to his institu-
tion, from ViiV.
•  Stéphane De Wit: none.
•  Jean-Christophe Goffard: has received consultancy 
fees from Gilead and ViiV.
•  Marie Laga: none.
•  Dominique Van Beckhoven: none.
•  Lieven Annemans: has received consultancy fees 
from Gilead Sciences Belgium.
Funding
This study, independently performed by Sebastian 
Vermeersch and supervised by Lieven Annemans, was 
funded by Gilead Sciences Belgium bvba/sprl.
Notes on contributors
Sebastian Vermeersch [PhD] is a passionate health-economic 
professional. After graduating as a computer science engi-
neer in 2003 and obtaining an additional degree in biomedi-
cal and clinical engineering, he obtained his PhD working in 
Ghent and Paris on practical applications of arterial stiffness 
modelling and the development of European reference values 
for arterial Stiffness. After a brief stay as research coordinator 
at the Heymans Institute of Pharmacology, he has been work-
ing at hict, an independent healthcare consultancy company, 
since 2012. As coresponsible of the Value Management team, 
his main interests lie in health-related value quantification 
and health-economics.
Steven Callens is an internist and infectious disease specialist 
at the Ghent University Hospital. He started his career as a 
district medical officer in Homa Bay on the shores of Lake 
Victoria in Kenya in the late nineties. He specialized at the 
University of Leuven and conducted his doctoral research on 
the treatment of children with HIV in Kinshasa, Democratic 
64   S. VERMEERSCH ET AL.
toestand op 31 december 2015 [Epidemiology of 
AIDS and HIV infectino in Belgium: situation on 31 
December 2015]. Brussel: Wetenschappelijk Instituut 
Volksgezondheid (WIV-ISP); 2016. 
[15]  Sasse A, Deblonde J, Van Beckhoven D. Epidemiologie 
van AIDS en HIV-infectie in België: toestand op 31 
december 2014 [Epidemiology of AIDS and HIV 
infectino in Belgium: situation on 31 December 2014]. 
Brussel: Wetenschappelijk Instituut Volksgezondheid 
(WIV-ISP); 2015.
[16]  Van Beckhoven D, Florence E, Ruelle J, Deblonde J, 
Verhofstede C, Callens S, et al. Good continuum of HIV 
care in Belgium despite weaknesses in retention and linkage 
to care among migrants. BMC Infect Dis. 2015;15:496.
[17]  Grant RM, Lama JR, Anderson PL, McMahan V, Liu 
AY, Vargas L, et al. Preexposure chemoprophylaxis for 
HIV prevention in men who have sex with men. N Engl 
J Med. 2010;363(27):2587–2599.
[18]  Choopanya K, Martin M, Suntharasamai P, Sangkum 
U, Mock PA, Leethochawalit M, et al. Antiretroviral 
prophylaxis for HIV infection in injecting drug users 
in Bangkok, Thailand (the Bangkok Tenofovir Study): a 
randomised, double-blind, placebo-controlled phase 3 
trial. The Lancet. 2013;381(9883):2083–2090.
[19]  Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, 
Rose CE, Segolodi TM, et al. Antiretroviral preexposure 
prophylaxis for heterosexual HIV transmission in 
Botswana. N Engl J Med. 2012;367(5):423–434.
[20]  Van Beckhoven D, Lacor P, Moutschen M, Piérard 
D, Sasse A, Vaira D, et al. Factors associated with the 
continuum of care of HIV-infected patients in Belgium. 
J Int AIDS Soc. 2014;17(4 Suppl 3):19534.
[21]  Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, 
Rose CE, Viall AH, et al. Human immunodeficiency 
virus transmission at each step of the care continuum 
in the United States. JAMA Intern Med. 2015 Apr 
1;175(4):588–596.
[22]  Yin Z, Rice B, Marrone G, Sönnerborg A, Suligoi B, 
Camoni L, et al. HIV acquisition post-migration: 
evidence from four European countries. Durban, South 
Africa. 2016 [cited 2017 Feb 3]. Available from: http://
programme.aids2016.org/Abstract/Abstract/8696
[23]  Wing EJ. HIV and aging. Int J Infect Dis IJID Off Publ 
Int Soc Infect Dis. 2016 Dec;53:61–68.
[24]  FOD Economie – SPF Economie – Statbel [Internet]. 
[cited 2017 Feb 28]. Available from: http://statbel.fgov.be/
[25]  Janssens D. Dagelijkse kostprijs van antiretrovirale 
therapie (ART) bij HIV-patiënten [Daily cost of 
antiretroviral therapy (ART) for HIV patients] [Master 
thesis]: Ghent University; Faculty of Medicine and 
Health Sciences; 2014.
[26]  Colin X, Lafuma A, Costagliola D, Smets E, Mauskopf 
J, Guillon P. Modelling the budget impact of darunavir 
in the treatment of highly treatment-experienced, 
HIV-infected adults in France. PharmacoEconomics. 
2010;28(Suppl 1):183–197.
[27]  Schackman BR, Eggman AA. Cost-effectiveness of pre-
exposure prophylaxis for HIV: a review. Curr Opin HIV 
AIDS. 2012 Nov;7(6):587–592.
[28]  Juusola JL, Brandeau ML. HIV treatment and 
prevention: a simple model to determine optimal 
investment. Med Decis Mak Int J Soc Med Decis Mak. 
2016 Apr;36(3):391–409.
[29]  Eaton JW, Johnson LF, Salomon JA, Bärnighausen 
T, Bendavid E, Bershteyn A, et al. HIV treatment as 
prevention: systematic comparison of mathematical 
models of the potential impact of antiretroviral 
therapy on HIV incidence in South Africa. PLoS Med. 
2012;9(7):e1001245.
ORCID
Sebastian Vermeersch    http://orcid.org/0000-0002-8979- 
8244
Steven Callens   http://orcid.org/0000-0002-7245-527X




 [1]  Nakagawa F, Phillips AN, Lundgren JD. Update 
on HIV in Western Europe. Curr HIV/AIDS Rep. 
2014;11(2):177–185.
 [2]  Maartens G, Celum C, Lewin SR. HIV infection: 
epidemiology, pathogenesis, treatment, and prevention. 
Lancet Lond Engl. 2014 Jul 19;384(9939):258–271.
 [3]  Ronti T, Vanden Berghe W, Nöstlinger C. Resultaten 
van de EMIS enquête 2010. Gegevens voor België 
[Results of the EMIS survey 2010. Data for Belgium] 
[Internet]. Antwerpen, Brussel: Prins Leopold Instituut 
voor Tropische Geneeskunde, Observatoire du sida et 
des sexualités; 2015. Available from: http://www.emis-
project.eu
 [4]  Heuker J, Sonder GJB, Stolte I, Geskus R, van den 
Hoek A. High HIV incidence among MSM prescribed 
postexposure prophylaxis, 2000-2009: indications for 
ongoing sexual risk behaviour. AIDS Lond Engl. 2012 
Feb 20;26(4):505–512.
 [5]  Elford J, Bolding G, Sherr L. High-risk sexual behaviour 
increases among London gay men between 1998 and 
2001: what is the role of HIV optimism? AIDS Lond 
Engl. 2002 Jul 26;16(11):1537–1544.
 [6]  Sionean C, Le BC, Hageman K, Oster AM, Wejnert 
C, Hess KL, et al. HIV Risk, prevention, and testing 
behaviors among heterosexuals at increased risk for 
HIV infection–National HIV behavioral surveillance 
system, 21 U.S. cities, 2010. Morb Mortal Wkly Rep 
Surveill Summ Wash DC 2002. 2014 Dec 19;63(14): 
1–39. 
 [7]  European Centre for Disease Prevention and Control/
WHO Regional Office for Europe. HIV/AIDS 
surveillance in Europe. Stockholm: ECDC; 2016.
 [8]  Quiros-Roldan E, Magoni M, Raffetti E, Donato F, 
Scarcella C, Paraninfo G, et al. The burden of chronic 
diseases and cost-of-care in subjects with HIV infection 
in a Health District of Northern Italy over a 12-year 
period compared to that of the general population. 
BMC Public Health. 2016;16:1146–1156.
 [9]  Nakagawa F, Miners A, Smith CJ, Simmons R, Lodwick 
RK, Cambiano V, et al. Projected lifetime healthcare 
costs associated with HIV infection. PLoS One. 
2015;10(4):e0125018.
[10]  Cairns G, McCormack S, Molina J-M. The European 
preexposure prophylaxis revolution. Curr Opin HIV 
AIDS. 2016 Jan;11(1):74–79.
[11]  Krakower DS, Jain S, Mayer KH. Antiretrovirals for 
primary HIV prevention: the current status of pre- and 
post-exposure prophylaxis. Curr HIV/AIDS Rep. 2015 
Mar;12(1):127–138.
[12]  Cohen MS, Chen YQ, McCauley M, Gamble T, 
Hosseinipour MC, Kumarasamy N, et al. Prevention 
of HIV-1 infection with early antiretroviral therapy. N 
Engl J Med. 2011 Aug 11;365(6):493–505.
[13]  Mayer KH, Ramjee G. The current status of the use of 
oral medication to prevent HIV transmission. Curr 
Opin HIV AIDS. 2015 Jul;10(4):226–232.
[14]  Sasse A, Deblonde J, Jaminé D, Ost C, Van Beckhoven 
D. Epidemiologie van AIDS en HIV-infectie in België: 
ACTA CLINICA BELGICA: INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY MEDICINE  65
Appendix 1. Model calculations
Introduction
The BELHIVPREV model consists of three core 
components:
(1)  An estimation of the annual number of new HIV 
diagnoses, based on the estimate of the total num-
ber of ‘infectious’ patients, and the degree of their 
infectiousness.
(2)  Estimation of the annual number of patients in medi-
cal follow-up, based on the calculated estimate of new 
HIV diagnoses entering follow-up, minus death and 
dropout added to those already in follow-up from 
previous years.
(3)  Integration of the effect of increasing the number of 
diagnosed patients on ART (immediate ART/TasP), 
decreasing the number of undiagnosed patients 
(outreach testing), and reducing the number of 
new HIV infections through prophylactic treatment 
(PrEP).
The following paragraphs detail the model mechanics and 
calculation approach for these three core components.
Propagative core model
Our model is based on a year-to-year estimate (Figure A1) of 
•  the number of patients in medical follow-up (# PIMF);
•  the number of new HIV diagnoses (# ND).
Estimating the number of new HIV diagnoses
The yearly number of new HIV infections is calculated year-
to-year from the estimated number of ‘infectious’ patients:
 
For the purposes of our model, an HIV patient was 
deemed to be ‘infectious’ (Figure A2) if: 
•  the patient was undiagnosed;
•  the patient was diagnosed, but had not initiated treatment;
•  the patient was being treated, but had not achieved a 




(#ND)year+1 = (#‘infectious’patients)year × (‘propagationfactor’)
(2)
(#‘infectious’patients) =(#unknown)
+ (#untreated) + (#VL ≥ 200)
Figure A1. Propagative core model.
Figure A2. Estimating the number of new HIV diagnoses.
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•  the number of patients in medical follow-up at the end 
of the previous year;
•  the number of newly diagnosed patients expected to 
enter follow-up, calculated as detailed above;
•  the expected mortality rate.
Or
 
The source data and resulting model values for these 
model parameters are outlined in the main text. The (% FU) 
and (retention) parameter s are assumed constant. Mortal-
ity varied year to year to take into account the effects of an 
ageing HIV population (as outlined in the main text).
Integrating the effects of outreach, immediate 
ART/TasP and PrEP
Outreach and immediate ART/TasP
The impact of immediate ART/TasP and outreach are includ-
ed in the model as modifiers to the (% ART) and (% UD) 
parameters in Equation (6)
PrEP
To integrate the effect of PrEP, a stepwise approach was im-
plemented.
First, a theoretical annual ‘population at risk’ was defined 
from the calculated annual new HIV diagnoses and pub-
lished HIV acquisition rates:
 
The impact of PrEP was modelled through a calculated 
decrease in the size of the annual ‘population at risk’, taking 
into account published PrEP effectiveness rates. The estimat-
ed number of infections avoided was calculated by recalcu-





















The number of undiagnosed patients (# unknown) was 
calculated taking into account the percentage of undiag-
nosed patients (% UD):
 
The number of untreated patients (# untreated) was calcu-
lated taking into account the percentage of patients on ART 
(% ART):
 
The number of patients not having achieved a controlled 
(undetectable; <200 copies/ml) viral load) was calculated 
taking into account the percentage of patients achieving a 
controlled viral load (% VL):
 
The source data and resulting model values for these 
model parameters are outlined in the main text.
Taking into account Equations (2)–(5), Equation (1) be-
comes:
 
The (% VL) and (propagation factor) parameters are as-
sumed constant.
Finally, based on reported figures for the Belgian contin-
uum of care, we assumed 90% (% FU) of newly diagnosed 
patients (# ND) enter HIV care (and are thus retained in the 
model).
Estimating the annual number of patients in 
medical follow-up
The estimated annual number of patients in medical fol-






(4)(#untreated) = (#PIMF)(1 − %ART)











1 − (% ART)year
)





Figure A3. Estimating the annual number of patients in medical follow-up.
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The model accounts for the difference in HIV infectious-
ness depending on the stage of the HIV care continuum in 
which an infectious patient can be (undiagnosed, diagnosed 
but untreated, treated and VL ≥ 200 copies/ml). To achieve 
this, scaled ‘propagation factors’ were used to calculate the 
estimated number of annual new HIV diagnoses taking into 
account the proportion of patients in each stage of the care 
continuum for each year in the model.
The model takes into account that a number of newly diag-
nosed HIV patients were migrants who had acquired HIV in 
their home country prior to their arrival in Belgium. These 
patients were not expected to be influenced by Belgian efforts 
in HIV prevention, i.e. the estimated number of infections 
newly diagnosed does not change, regardless of the addition-
al prevention effort simulated.
reduced ‘population at risk’, using the aforementioned HIV 
infection rates.
 
Taking into account (sub)population differences
The model allows us to specify subpopulation-specific values 
for all model parameters. The following parameters were im-
plemented population-specific:
•  the percentage of undiagnosed patients;
•  the HIV acquisition and transmission rates used to cal-
culate the size of the ‘population at risk’ for estimation 






(PrEP effectiveness)(HIV infection )
Figure A4. Integrating the effect of outreach and immediate ART/TasP
